The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.

This invention relates to multi-specific molecules, such as long acting multi-specific antibodies. Also disclosed are related methods.

Provided herein are bivalent, bispecific binding proteins that specifically bind to two different HIV-1 Env protein epitopes.

The present invention relates to anti-brain target agents and therapeutic uses thereof.

Provided herein are bivalent, bispecific binding proteins that specifically bind to two different HIV-1 Env protein epitopes.

Described herein are compositions of modified binding agents and modified carrier proteins, as well as nanoparticle complexes comprising modified binding agents and modified carrier proteins with optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic.

The present disclosure provides nucleic acid carriers comprising targeting agents, pharmaceutical compositions comprising the same, and methods of making and using the same.

This invention relates to multi-specific molecules, such as long acting multi-specific antibodies. Also disclosed are relates methods.

Provided herein are antigen binding polypeptides and complexes thereof having agonist activity. Also provided are methods for screening for complexes or polypeptides having agonist activity, enhancing the agonist activity of a polypeptide, and for agonizing a cell surface receptor using the complexes and polypeptide described herein.

The present disclosure provides nucleic acid carriers comprising one or more layers comprising multiple monomers, wherein each monomer comprises: a first and a second oligonucleotide; wherein a central portion of each of the first and second oligonucleotides is complementary to each other, forming a double-stranded region, wherein the two terminal portions of the first oligonucleotide are not complementary to the two terminal portions of the second oligonucleotide, forming four terminal arms; and at least one targeting agent conjugated to at least one peripheral terminal arm, wherein when the at least one targeting agent is an miRNA. The present disclosure also provides pharmaceutical composition comprising any of the nucleic acid carriers described herein, and a pharmaceutically acceptable vehicle. The present disclosure also provides methods of inducing an immune response in an animal comprising administering to the animal any of the nucleic acid carriers described herein.